CardioTech nears human trials for synthetic CABG (coronary artery bypass surgery):
This article was originally published in Clinica
Executive Summary
CardioTech International says that it is preparing to enter clinical trials outside the US to assess its synthetic coronary artery bypass graft (CABG), after recently concluding bench and pre-clinical animal trials of the device. The polyurethane-based product, called CardioPass, could address a market that is expected to exceed $1.5bn annually, says the Woburn, Massachusetts firm.